• Abdel-Hamid M, Brüne M. Neuropsychological aspects of delusional disorder. Curr Psychiatry Rep 2008;10:229-34.
• Manschreck TC, Khan NL: Recent advances in the treatment of delusional disorder. Can J Psychiatry 2006;51:114–9.
• Myers WC, Ruiz R: Aripiprazole and psychotherapy for delusional disorder, erotomanic type. J Am Acad Child Adolesc Psychiatry 2004;43:1069-70.
• Rocha FL, Hara C. Aripiprazole in delusional parasitosis: Case report. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:784-6.
• Freudenmann RW. A case of delusional parasitosis in severe heart failure. Olanzapine within the framework of a multimodal therapy. Nervenarzt 2003;74: 591–5.
• Chae BJ, Kang BJ. Quetiapine for hypersexuality and delusional jealousy after stroke. J Clin Psychopharmacol 2006;26:331–2.
• Kitamura H. A case of somatic delusional disorder that responded to treatment with risperidone. Psychiatry Clin Neurosci. 1997;51:337.
• Monkul SE, Akdede BB. Aripiprazole: A new atypical antipsyhotic drug. Bulletin of Clinical Psychopharmacology 2005;15:198-203.
• Soygür H. Pharmacokinetic and pharmacodynamic characteristics of aripiprazole. Bulletin of Clinical Psychopharmacology 2008:18(Suppl. 1):1-6.
• Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20:612-27.
• Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 2004;18:375-83.
• Alptekin K. New generation antipsychotics in the treatment of schizophrenia: dopamine stabilizing agents and aripiprazole. Bulletin of Clinical Psychopharmacology 2008:18(Suppl. 1):21-6.
• Potkin SG, Saha AR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681–90.
• Chrzanowski WK, Marcus RN. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259-66.
• Dimopoulos N, Mitsonis C, Psarra V. Delusional disorder, somatic type treated with aripiprazole mirtazapine combination. J Psychopharmacol 2008;22:812-4.

Vancouver

Duvar H, Şengül C, Herken H. Aripiprazole in Delusional Disorder. Eur J Gen Med. 2010;7(4):433-5. https://doi.org/10.29333/ejgm/82901

APA

Duvar, H., Şengül, C., & Herken, H. (2010). Aripiprazole in Delusional Disorder. European Journal of General Medicine, 7(4), 433-435. https://doi.org/10.29333/ejgm/82901

AMA

Duvar H, Şengül C, Herken H. Aripiprazole in Delusional Disorder. Eur J Gen Med. 2010;7(4), 433-435. https://doi.org/10.29333/ejgm/82901

Chicago

Duvar, Halide, Cem Şengül, and Hasan Herken. "Aripiprazole in Delusional Disorder". European Journal of General Medicine 2010 7 no. 4 (2010): 433-435. https://doi.org/10.29333/ejgm/82901

Harvard

Duvar, H., Şengül, C., and Herken, H. (2010). Aripiprazole in Delusional Disorder. European Journal of General Medicine, 7(4), pp. 433-435. https://doi.org/10.29333/ejgm/82901

MLA

Duvar, Halide et al. "Aripiprazole in Delusional Disorder". European Journal of General Medicine, vol. 7, no. 4, 2010, pp. 433-435. https://doi.org/10.29333/ejgm/82901